Company Filing History:
Years Active: 2007
Title: Innovations of Erik Wallen in Prolyl Oligopeptidase Inhibition
Introduction
Erik Wallen is a notable inventor based in Kuopio, Finland. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit prolyl oligopeptidase. His work is particularly relevant for potential treatments of neurodegenerative diseases such as Alzheimer's.
Latest Patents
Wallen holds a patent for "Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use." This patent includes compounds of the formula (I), where the symbol aa represents a residue of an α-amino acid. The invention outlines methods for preparing these compounds and their application as prolyl oligopeptide inhibitors, which could be crucial in treating Alzheimer's disease. He has 1 patent to his name.
Career Highlights
Erik Wallen is associated with Orion Corporation, a leading pharmaceutical company in Finland. His role at Orion has allowed him to focus on innovative research and development in the field of drug discovery. His expertise in medicinal chemistry has positioned him as a valuable asset to the company.
Collaborations
Wallen has collaborated with notable colleagues such as Jukka Gynther and Pekka Männistö. These collaborations have fostered a productive research environment, leading to advancements in their shared field of study.
Conclusion
Erik Wallen's contributions to the field of prolyl oligopeptidase inhibition highlight his innovative spirit and dedication to addressing critical health challenges. His work continues to pave the way for potential breakthroughs in the treatment of Alzheimer's disease.